Biofourmis lands $100M in Series C funding round

The Company will use funding to bring new digital therapeutic solutions to market

Stethoscope on a computer keyboard

Biofourmis, which combines AI-based data analytics with medical-grade biosensors to provide personalized, predictive care, announced it’s completed a $100 million Series C financing round. SoftBank Vision Fund 2 led the funding round, with existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI participating too.

Biofourmis closed its $35 million Series B funding round just a year ago and has since increased its revenue significantly through new partnerships with seven pharmaceutical companies and 10 health systems worldwide, including Novartis, AstraZeneca and Mayo Clinic. 

Biofourmis says it will use the funding to develop, validate and bring new digital therapeutic solutions for cardiology, respiratory, oncology and pain treatments to the market. The company also plans to focus on the U.S. and Asian markets, including Asia Pacific, China and Japan.

Biofourmis CEO Kuldeep Singh Rajput said, "Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy.”

“With this new funding, we will accelerate our global expansion, advance our digital therapeutics pipeline, develop additional care pathways and drive deeper integration with our health system, hospital, pharmaceutical and clinical research clients and partners," Kuldeep added.

Biofourmis also announced an alignment of its internal operations. The new business structure will include two verticals: Biofourmis Therapeutics, which will focus on developing clinically validated software-based therapeutics and Biofourmis Health, which will leverage the company's AI-based remote monitoring system to lower health care costs and improve patient outcomes.

"In the last seven months, healthcare has fast-forwarded by at least five years," Rajput said. "Despite a challenging global economic environment due to the COVID-19 pandemic, we expect that our latest funding round will accelerate Biofourmis' plans to rapidly scale to support more healthcare provider, pharmaceutical and health plan clients across the world. We will continue to drive an evolution toward a more personalized and predictive remote method of care delivery that patients prefer and that enables better outcomes."

Featured Resources

The complete guide to changing your phone system provider

Optimise your phone system for better business results

Download now

Simplify cluster security at scale

Centralised secrets management across hybrid, multi-cloud environments

Download now

The endpoint as a key element of your security infrastructure

Threats to endpoints in a world of remote working

Download now

2021 state of IT asset management report

The role of IT asset management for maximising technology investments

Download now

Recommended

RS Analyze monitors health care vendors’ performance
business analytics

RS Analyze monitors health care vendors’ performance

26 Oct 2020
eVisit will expand its telehealth offering after $14 million funding round
video conferencing

eVisit will expand its telehealth offering after $14 million funding round

20 Oct 2020
VectorCare expands offerings to meet surging mobile health care demands
software as a service (SaaS)

VectorCare expands offerings to meet surging mobile health care demands

15 Oct 2020
Google and Amwell team up to boost telehealth services
Cloud

Google and Amwell team up to boost telehealth services

25 Aug 2020

Most Popular

Best MDM solutions 2020
mobile device management (MDM)

Best MDM solutions 2020

21 Oct 2020
Weekly threat roundup: Chrome, Citrix and WordPress
Security

Weekly threat roundup: Chrome, Citrix and WordPress

23 Oct 2020
What is Neuralink?
Technology

What is Neuralink?

24 Oct 2020